WO2006110367A3 - Procedes et compositions pour toxines mycoplasma - Google Patents

Procedes et compositions pour toxines mycoplasma Download PDF

Info

Publication number
WO2006110367A3
WO2006110367A3 PCT/US2006/012266 US2006012266W WO2006110367A3 WO 2006110367 A3 WO2006110367 A3 WO 2006110367A3 US 2006012266 W US2006012266 W US 2006012266W WO 2006110367 A3 WO2006110367 A3 WO 2006110367A3
Authority
WO
WIPO (PCT)
Prior art keywords
toxins
methods
mycoplasma
compositions
domains
Prior art date
Application number
PCT/US2006/012266
Other languages
English (en)
Other versions
WO2006110367A2 (fr
Inventor
Joel Barry Baseman
Thirumalai Rengasamy Kannan
Original Assignee
Univ Texas
Joel Barry Baseman
Thirumalai Rengasamy Kannan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Joel Barry Baseman, Thirumalai Rengasamy Kannan filed Critical Univ Texas
Priority to US11/887,995 priority Critical patent/US20090104185A1/en
Publication of WO2006110367A2 publication Critical patent/WO2006110367A2/fr
Publication of WO2006110367A3 publication Critical patent/WO2006110367A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/30—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycoplasmatales, e.g. Pleuropneumonia-like organisms [PPLO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des toxines mycoplasma, des domaines/fragments biologiquement actifs de ces toxines, des anticorps pour ces toxines, des protéines de fusion thérapeutiques comprenant ces toxines et/ou des domaines/fragments biologiquement actifs de ces toxines et des acides nucléiques codant pour ces toxines et ces protéines de fusion. Cette invention concerne aussi des techniques de traitement et/ou de prévention de maladies et de pathologies au moyen de ces compositions.
PCT/US2006/012266 2005-04-07 2006-03-31 Procedes et compositions pour toxines mycoplasma WO2006110367A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/887,995 US20090104185A1 (en) 2005-04-07 2006-03-31 Methods and Compositions for Mycoplasma Toxins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2005/011897 WO2006110132A1 (fr) 2005-04-07 2005-04-07 Methodes et compositions pour les exotoxines mycoplasma pneumoniae
USPCT/US2005/011897 2005-04-07

Publications (2)

Publication Number Publication Date
WO2006110367A2 WO2006110367A2 (fr) 2006-10-19
WO2006110367A3 true WO2006110367A3 (fr) 2006-12-21

Family

ID=37087319

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2005/011897 WO2006110132A1 (fr) 2005-04-07 2005-04-07 Methodes et compositions pour les exotoxines mycoplasma pneumoniae
PCT/US2006/012266 WO2006110367A2 (fr) 2005-04-07 2006-03-31 Procedes et compositions pour toxines mycoplasma

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2005/011897 WO2006110132A1 (fr) 2005-04-07 2005-04-07 Methodes et compositions pour les exotoxines mycoplasma pneumoniae

Country Status (1)

Country Link
WO (2) WO2006110132A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030176331A1 (en) * 2001-02-12 2003-09-18 Rosenblum Michael G. Modified proteins, designer toxins, and methods of making thereof
US20040191260A1 (en) * 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US20060057155A1 (en) * 2001-03-30 2006-03-16 Vega Masignani Adp-ribosylating bacterial toxins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030176331A1 (en) * 2001-02-12 2003-09-18 Rosenblum Michael G. Modified proteins, designer toxins, and methods of making thereof
US20060057155A1 (en) * 2001-03-30 2006-03-16 Vega Masignani Adp-ribosylating bacterial toxins
US20040191260A1 (en) * 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BARILE ET AL.: "Experimentally induced septic arthritis in chimpanzees infected with Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum", CLINICAL INFECTIOUS DISEASES, vol. 18, no. 5, 1994, pages 694 - 703 *
DANDEKAR ET AL.: "Re-annotating the Mycoplasma pneumoniae genome sequence: adding value, function and reading frames", NUCLEIC ACIDS RES., vol. 28, no. 7, 2000, pages 3278 - 3288 *
HOTT ET AL.: "Skeletal muscle-specific immunotoxin for the treatment of focal muscle spasm", NEUROLOGY, vol. 50, no. 2, 1998, pages 485 - 491 *
KANNAN AND BASEMAN: "ADP-ribosylating and vacuolating cytotoxin of My. pneumoniae represents unique virulence determinant among bacterial pathogens", PROC. NATL. ACAD. SCI., vol. 103, no. 17, 25 April 2006 (2006-04-25), pages 6724 - 6729 *
KANNAN ET AL.: "Identification and characterization of human surfactant protein A binding protein of M. pnseumoniae", INFECT. IMMUN., vol. 73, no. 5, May 2005 (2005-05-01), pages 2828 - 2834 *
PALLEN ET AL.: "An abundance of bacterial ADP-ribosyltransferase-implications for the origins of exotoxins", TRENDS IN MICROBIOLOGY, vol. 9, no. 7, July 2001 (2001-07-01), pages 302 - 307 *
SASAKI ET AL.: "The complete genomic sequence of Mycoplasma penetrans, an intracellular bacterial pathogen in humans", NUCLEIC ACIDS RES., vol. 30, no. 23, 2002, pages 5293 - 5300 *

Also Published As

Publication number Publication date
WO2006110367A2 (fr) 2006-10-19
WO2006110132A1 (fr) 2006-10-19

Similar Documents

Publication Publication Date Title
WO2005063820A3 (fr) Proteines de fusion de il-7
WO2007091250A3 (fr) Enzymotherapie de remplacement pour le traitement des maladies lysosomiales
WO2005077042A3 (fr) Proteines hybrides d'albumine
WO2007021494A3 (fr) Proteines de fusion avec l'albumine
WO2008033413A3 (fr) Protéines de fusion d'albumine
WO2007146038A3 (fr) Protéines de fusion d'albumine
WO2007067730A3 (fr) Anticorps monoclonaux humains contre la proteine tyrosine kinase 7 (ptk7) et procedes pour utiliser des anticorps anti-ptk7
AU2002305450A1 (en) Proteomimetic compounds and methods
DE60028970D1 (de) An her2 bindende peptidverbindungen
WO2004110472A3 (fr) Proteines de fusion
WO2007011693A3 (fr) Compositions de cellules souches derivees du placenta, utilisees dans le traitement de cancers
NO20055209D0 (no) Peptabody for cancerbehandling
WO2003060071A3 (fr) Proteines hybrides d'albumine
MX2008009886A (es) Anticuerpos que enlazan par-2.
WO2006087637A3 (fr) Anticorps
WO2007064727A3 (fr) 'penetrabodies' : administration ciblee a mediation par recepteur de fragments d'anticorps fonctionnellement actifs dans le cytosol pour traiter des infections et des maladies chroniques
WO2005056600A3 (fr) Anticorps monoclonaux se liant ou neutralisant le virus de la dengue
WO2006060680A3 (fr) Variants de la proteine mda-7 presentant une activite antiproliferative
WO2007059341A3 (fr) Modulateurs de la proteine kinase a base de pyrazolothiazole
WO2006047728A3 (fr) Genes bmp et proteines de fusion
WO2005030793A3 (fr) Anticorps se liant aux cxcr3 humains
WO2006133457A3 (fr) Variants morphogenetiques osseux, compositions et methodes de traitement
WO2004099388A3 (fr) Complexes de polypeptides cbl-b et methodes associees
WO2004094476A3 (fr) Compositions et methodes se rapportant a stop-1
WO2006122971A3 (fr) Traitement de maladies a l'aide d'un systeme d'expression regulee, ameliore

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06749143

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 11887995

Country of ref document: US